We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Testing for Proteins in Saliva Could Help Detect COVID-19 and Predict Severity

By LabMedica International staff writers
Posted on 07 Apr 2022

Researchers have identified a family of proteins that is significantly elevated in the saliva of patients hospitalized with COVID-19. More...

The proteins, known as ephrin ligands, could potentially serve as a biomarker to help doctors identify patients who are at risk for serious illness.

For the study, researchers at the University of Utah Health (Salt Lake City, UT, USA) analyzed saliva samples collected from patients with respiratory symptoms. Out of these, 67 patients tested positive for COVID-19 while 64 patients did not. The researchers found that the presence of ephrin ligands in saliva was strongly associated with the diagnosis of severe COVID-19.

The study findings could help shed light on the biological processes involved in severe reactions to COVID-19 infection, according to the researchers. Previous studies suggest ephrins play a role in injury and inflammation. The scientists say more research is needed to determine whether ephrin concentrations are linked with a higher likelihood of hospitalization, critical illness or death. In addition, as new viral variants emerge, it can be difficult to tell whether existing COVID-19 tests are able to accurately detect infections involving new variants. Looking for ephrins in saliva could offer a simple, non-invasive way to provide corroborating evidence when there is inconsistency between test results and the clinical picture.

“Ephrins are detectable in saliva samples and could serve as adjunct markers to monitor COVID-19 disease progression,” said study author Erika Egal, DVM, PhD, a postdoctoral fellow at University of Utah Health. “We can collect saliva without harm or discomfort for most patients, which can reveal patient responses to COVID-19 and potentially guide care.”

“Saliva is packed with information beyond detecting the COVID-19 infection itself,” said Patrice Mimche, PhD, at University of Utah Health in Salt Lake City.. “We demonstrate that immune cells, cytokines and soluble proteins can be reliably measured from saliva samples. Our findings provide a starting point for investigations looking into causal pathways between infection and bad medical outcomes.”

Related Links:
University of Utah Health 


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Online QC Software
Acusera 24•7
New
Urine Analyzer
respons® UDS100
New
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.